NIH, FDA to tighten, review consulting rules as Congressional inquiry continues.
In this 12-page issue: Moonlighting by NCI and FDA scientists conflicted with CRADA work, House Subcommittee on Oversight and Investigations says.
HHS lawyer tells of pressure to allow former NCI Director Richard Klausner to receive $40,000 prize.
Former NIH Director Varmus calls for more oversight of conflicts, expresses surprise at growth of Title 42 program.
In Brief: ASCO awards career development grants.
Funding Opportunities listed.
Trending Stories
- Oncologist Rachna Shroff endows award to outlast her cancer diagnosis
“Because of my health, I have a profound desire to see this endowment come to fruition now” - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Letai: MCEDs are a “great ideal”—alas, the data don’t support widespread use
“Projecting sub-ideal tests across a large population can cause harm,” Letai says, as Galleri cruises toward FDA approval - As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Oncology has a semantics problem: How do we define “early stage”?
